OmniAb, Inc. operates as a drug discovery company. The firm focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform | $6 |
| Apr-21-23 | Initiated | The Benchmark Company | Buy | $8 |
| Apr-13-23 | Initiated | Craig Hallum | Buy | $10 |
| Feb-22-23 | Initiated | Cowen | Outperform | $10 |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy | $11 |
| Dec-20-22 | Initiated | Truist | Buy | $10 |
| Dec-16-22 | Initiated | Credit Suisse | Outperform | $13 |
| Nov-29-22 | Initiated | SVB Leerink | Outperform | $6 |
| Nov-28-22 | Initiated | Stifel | Buy | $12 |